Editorial
Year 2021,
Volume: 2 Issue: 1, 20 - 21, 03.07.2021
Keywords
References
- 1. Organization WH. Coronavirus (COVID-19). 2020. 2020.
- 2. Mishra E, Goyal AK, Rath G. Recent advances in drug delivery systems in antiviral therapy. 2018.
- 3. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
- 4. Oldfield V, Plosker GL. Lopinavir/ritonavir. Drugs. 2006;66(9):1275-99.
- 5. Llibre JM. Development of darunavir over the entire spectrum of HIV infection. Enfermedades Infecciosas y Microbiologia Clinica. 2018;36:3-9.
- 6. Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19. Journal of medical virology. 2020.
- 7. Cao Y-c, Deng Q-x, Dai S-x. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Medicine and Infectious Disease. 2020:101647.
- 8. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection. 2020.
- 9. Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019 nCoV) in vitro [published online February 4, 2020]. Cell Res doi.10.
- 10. Samuel CE. Antiviral actions of interferons. Clinical microbiology reviews. 2001;14(4):778-809.
- 11. Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin. 2020;72(3):159-64.
- 12. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. International journal of antimicrobial agents. 2020:105954.
- 13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9.
- 14. Philippe G, Jean C, Lagier P. P.; Van, TH; Line, M.; et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Journal of Antimicrobial agents. 2020.
- 15. Wu SC. Progress and Concept for COVID‐19 Vaccine Development. Biotechnology Journal. 2020.
- 16. Çiftçiler R, Haznedaroğlu İ C. COVID-19, Renin-Angiotensin System, and Hematopoiesis. Turk J Haematol. 2020;37(3):207-8.
Year 2021,
Volume: 2 Issue: 1, 20 - 21, 03.07.2021
References
- 1. Organization WH. Coronavirus (COVID-19). 2020. 2020.
- 2. Mishra E, Goyal AK, Rath G. Recent advances in drug delivery systems in antiviral therapy. 2018.
- 3. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
- 4. Oldfield V, Plosker GL. Lopinavir/ritonavir. Drugs. 2006;66(9):1275-99.
- 5. Llibre JM. Development of darunavir over the entire spectrum of HIV infection. Enfermedades Infecciosas y Microbiologia Clinica. 2018;36:3-9.
- 6. Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19. Journal of medical virology. 2020.
- 7. Cao Y-c, Deng Q-x, Dai S-x. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Medicine and Infectious Disease. 2020:101647.
- 8. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection. 2020.
- 9. Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019 nCoV) in vitro [published online February 4, 2020]. Cell Res doi.10.
- 10. Samuel CE. Antiviral actions of interferons. Clinical microbiology reviews. 2001;14(4):778-809.
- 11. Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin. 2020;72(3):159-64.
- 12. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. International journal of antimicrobial agents. 2020:105954.
- 13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9.
- 14. Philippe G, Jean C, Lagier P. P.; Van, TH; Line, M.; et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Journal of Antimicrobial agents. 2020.
- 15. Wu SC. Progress and Concept for COVID‐19 Vaccine Development. Biotechnology Journal. 2020.
- 16. Çiftçiler R, Haznedaroğlu İ C. COVID-19, Renin-Angiotensin System, and Hematopoiesis. Turk J Haematol. 2020;37(3):207-8.
There are 16 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Olgu Sunumu |
| Authors | |
| Publication Date | July 3, 2021 |
| Submission Date | December 7, 2020 |
| Acceptance Date | December 21, 2020 |
| Published in Issue | Year 2021 Volume: 2 Issue: 1 |
